CGON vs. DNLI, VCEL, IMCR, KYMR, ACLX, BEAM, DNA, SANA, APGE, and FUSN
Should you be buying CG Oncology stock or one of its competitors? The main competitors of CG Oncology include Denali Therapeutics (DNLI), Vericel (VCEL), Immunocore (IMCR), Kymera Therapeutics (KYMR), Arcellx (ACLX), Beam Therapeutics (BEAM), Ginkgo Bioworks (DNA), Sana Biotechnology (SANA), Apogee Therapeutics (APGE), and Fusion Pharmaceuticals (FUSN). These companies are all part of the "biological products, except diagnostic" industry.
CG Oncology (NASDAQ:CGON) and Denali Therapeutics (NASDAQ:DNLI) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation, community ranking and profitability.
CG Oncology has a net margin of 0.00% compared to Denali Therapeutics' net margin of -36.51%. CG Oncology's return on equity of 0.00% beat Denali Therapeutics' return on equity.
In the previous week, CG Oncology had 7 more articles in the media than Denali Therapeutics. MarketBeat recorded 10 mentions for CG Oncology and 3 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.04 beat CG Oncology's score of -0.27 indicating that Denali Therapeutics is being referred to more favorably in the news media.
26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 7.9% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Denali Therapeutics received 433 more outperform votes than CG Oncology when rated by MarketBeat users. However, 71.43% of users gave CG Oncology an outperform vote while only 67.38% of users gave Denali Therapeutics an outperform vote.
CG Oncology has higher earnings, but lower revenue than Denali Therapeutics.
CG Oncology presently has a consensus price target of $61.75, suggesting a potential upside of 50.61%. Denali Therapeutics has a consensus price target of $41.22, suggesting a potential upside of 167.16%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Denali Therapeutics is more favorable than CG Oncology.
Summary
Denali Therapeutics beats CG Oncology on 8 of the 15 factors compared between the two stocks.
Get CG Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CG Oncology Competitors List
Related Companies and Tools
